LAMP-CRISPR kit for detecting lung cancer and application of LAMP-CRISPR kit
Through LAMP-CRISPR technology combined with the characteristics of circular RNA, the problem of time-consuming and low accuracy in early diagnosis of lung cancer is solved, and the rapid and accurate detection of peripheral blood lung cancer markers is achieved, which simplifies operation and improves the specificity of the detection. and sensitivity.
Patent Information
- Application Number
- CN202411462951.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-19
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art has problems such as long time, complex process, low accuracy and sampling trauma in the early diagnosis of lung cancer, making it difficult to effectively detect lung cancer markers in peripheral blood.
Using LAMP-CRISPR-based detection technology, the characteristics of circular RNA are used to bind Cas12b protein, and specific primers and sgRNA are designed. The premix solution of a tube fluorescent probe is used to perform rapid and accurate detection, and combined with LAMP and CRISPR technology is optimized into one section. simplifies operation and improves accuracy.
It realizes rapid, accurate and non-invasive lung cancer marker detection, reduces the difficulty and cycle of experimental operations, improves the specificity and sensitivity of the detection, and can interpret the results in a short time, which has important scientific research and application value.
Smart Images

Figure CN119061146A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of molecular biology technology CRISPR and nucleic acid detection technology, and relates to a detection technology based on LAMP combined with CRISPR / Cas12b. Specifically, it is about a primer set and a kit of LAMP-CRISPR for detecting lung cancer. Background Art
[0002] In 2000, Japanese scholar Notomi published a new isothermal nucleic acid amplification technology suitable for genetic diagnosis in the journal Nucleic Acids Res, namely loop-mediated isothermal amplification (LAMP). This method relies on four primers (two outer primers and two inner primers) that recognize six specific fragments of conserved sequence DNA and a strand displacement DNA polymerase (Bst DNA polymerase). In the LAMP detection system, gene amplification and product detection can be completed in one step, but the false positive rate is slightly higher than that of PCR, and it is easily contaminated by aerosols. Currently, mineral oil and UDG enzyme are commonly added to prevent contamination.
[0003] CRISPR comes from the immune system of microorganisms. This engineering editing system uses an enzyme to cut a small RNA that serves as a guide tool into DNA, which can cut or make other changes at this point. Among them, Cas12a / Cas12b / Cas13a not only has cis-cutting ability, but also has trans-cutting ability. While binding to the target site, it activates the trans-cutting ability to trans-cut nearby ssDNA and release fluorescent signals. However, Cas12a / Cas12b / Cas13a proteins cannot amplify target sequence templates, and appear to be a little struggling when facing low-copy target sequences, so there is a technical fusion of LAMP-CRISPR.
[0004] Lung cancer, also known as primary bronchial lung cancer, is the most common lung malignancy originating from the trachea, bronchial mucosa or glands. Globally, the incidence and mortality of lung cancer are extremely high and on the rise. The incidence and mortality of lung cancer in men rank first among malignant tumors. The clinical symptoms of lung cancer are closely related to the size, type, development stage, site of occurrence, complications and metastasis of the tumor. Common symptoms include cough, blood in sputum, wheezing, chest pain, etc. There may be no obvious symptoms in the early stages of the disease, and some patients are accidentally discovered during physical examinations. It is difficult to detect early lung cancer patients during physical examinations, and CT shadows are not obvious and are easily overlooked. Products are needed to assist CT in making timely diagnosis of early lung cancer patients to avoid missing the best treatment time.
[0005] Circular RNA is a special type of non-coding RNA molecule. Unlike traditional linear RNA (linear RNA), it is a closed RNA molecule formed by reverse splicing. CircRNA does not have a 5' end cap and a 3' end poly (A) tail. Through exon cyclization or intron cyclization, the 3' and 5' ends are connected to form a complete circular structure to avoid degradation by nuclease exonucleases. Therefore, it is more stable and conservative than linear RNA. Circular RNA has a closed circular structure, a longer half-life than linear RNA, specific reverse splicing sites, tissue expression specificity, disease specificity, etc. Most of them exist in the cytoplasm, and a small part exists in the nucleus. Most of them are non-coding RNAs, and the sequences are highly conserved. However, the overall expression abundance is lower than that of mRNA, and the proportion is still more than 10%. Summary of the invention
[0006] The purpose of the present invention is to provide a method and reagent for detecting peripheral blood lung cancer markers based on LAMP-CRISPR. The method belongs to in vitro diagnosis, and the sample source is peripheral circulating blood of non-invasive samples. The marker has a high correlation with lung cancer and a stable structure, which is not easy to degrade. The reagent has high accuracy, short time required, and simple operation, and includes the following steps:
[0007] Based on the above, the purpose of the present invention is to provide a reagent and method for detecting peripheral blood lung cancer markers based on LAMP-CRISPR. The present invention provides a method and reagent for detecting peripheral blood lung cancer markers based on LAMP-CRISPR, which overcomes the problems of long time consumption, complex procedures, low accuracy, and sampling trauma in existing methods, and has important scientific research and application value.
[0008] The present invention first provides a LAMP primer set, which comprises: FIP with a nucleotide sequence of SEQ ID NO: 2, BIP with a nucleotide sequence of SEQ ID NO: 3, F3 with a nucleotide sequence of SEQ ID NO: 4, and B3 with a nucleotide sequence of SEQ ID NO: 5.
[0009] In one embodiment according to the present invention, the LAMP primer set optionally comprises the following loop primers: LF having a nucleotide sequence of SEQ ID NO: 6 and LB having a nucleotide sequence of SEQ ID NO: 7.
[0010] The present invention also provides an sgRNA, which is designed based on a cricRNA marker having a nucleotide sequence of SEQ ID NO: 9 and specifically binds to the Cas12b protein.
[0011] In one embodiment according to the present invention, the nucleotide sequence of sgRNA is SEQ ID No:1.
[0012] Another aspect of the present invention provides a LAMP-CRISPR kit, which includes the above-mentioned LAMP primer set, sgRNA, Cas12b protein, reverse transcriptase, DNA polymerase, fluorescently labeled probe and LAMP-CRISPR premix;
[0013] The LAMP-CRISPR premix contains: Bst DNA polymerase at a concentration of 0.4U / μL to 1.6U / μL; reverse transcriptase at a concentration of 0.5U / μL to 1U / μL; Cas12b at a concentration of 1nM to 15nM; and a buffer;
[0014] In one embodiment according to the present invention, the DNA polymerase is BST DNA polymerase or M-MLV, preferably Bst DNA polymerase at a concentration of 0.4U / μL to 1.6U / μL;
[0015] In one embodiment according to the present invention, the LAMP-CRISPR premix comprises: DNA polymerase 1.6U / μL, reverse transcriptase 1U / μL, Cas12b 10nM and buffer;
[0016] In one embodiment according to the present invention, the buffer comprises:
[0017] Tris-HCl PH8.0 1mM~40mM, (NH4)2SO4 5mM~15mM; KCl 5mM~100mM, betaine 100mM~1.5M, MgSO4 2mM~25mM, Triton-X100 0.01%~1%, BSA concentration is 10μg / mL~500μg / mL;
[0018] In one embodiment according to the present invention: Tris-HCl pH 8.0 20 mM, (NH4)2SO4 5 mM, KCl 10 mM, betaine 400 mM, MgSO4 8 mM, Triton-X100 0.1% and BSA 100 μg / mL.
[0019] In one embodiment of the present invention, the nucleotide sequence of the fluorescent labeling probe is as shown in SEQ ID NO: 8; preferably, the added amount is 0.1 μM to 1 μM, preferably 0.5 μM.
[0020] According to one embodiment of the present invention, the concentration of each primer in the LAMP primer set is:
[0021] The concentration of FIP primer is 0.8mM to 3.2mM;
[0022] The concentration of BIP primer ranged from 0.8 mM to 3.2 mM;
[0023] The concentration of F3 primer is 0.1mM to 0.4mM;
[0024] The concentration of B3 primer is 0.1mM to 0.4mM;
[0025] The concentration of LF primer is 0.2mM to 0.8mM;
[0026] The concentration of LB primer is 0.2mM to 0.8mM;
[0027] In one embodiment according to the present invention, the concentration of the FIP primer is 1.4 mM;
[0028] The concentration of the BIP primer is 1.4 mM; and / or
[0029] The concentration of the F3 primer is 0.2 mM; and / or
[0030] The concentration of the B3 primer is 0.2 mM; and / or
[0031] The concentration of LF primer is 0.4 mM; and / or
[0032] The concentration of LB primer was 0.4 mM.
[0033] In one embodiment of the present invention, the reaction procedure is: react at 60-65° C. for 15-30 min and then perform fluorescence detection.
[0034] Another aspect of the present invention provides use of the above-mentioned LAMP primer set and / or the above-mentioned sgRNA in preparing a LAMP-CRISPR kit for detecting lung cancer markers in a sample.
[0035] In one embodiment of the present invention, the sample is peripheral blood.
[0036] In one embodiment of the present invention, the sample is a plasma sample obtained by extracting peripheral blood, adding an anticoagulant and mixing, and taking the supernatant after centrifugation; preferably, the lung cancer marker is cricRNA with an amino acid sequence of SEQ ID NO:9.
[0037] The beneficial effects of the above technical solution of the present invention are as follows:
[0038] 1) The present invention uses a tube-type fluorescent probe premix, which contains: LAMP primer, BST DNA Polymerase, Cas12a / Cas12b / Cas13a, M-MLV, BSA, Tris-HCl PH8.0, KCl, (NH4)2SO4, betaine, MgSO4, Triton-X100; fluorescent labeled probe and sgRNA are added before detection. The present invention has high accuracy, short time required, and simple operation.
[0039] 2) The present invention utilizes cricRNA (hereinafter referred to as circular RNA) in peripheral blood. Circular RNA is a special type of non-coding RNA molecule. Unlike traditional linear RNA (linear RNA), it is a closed RNA molecule formed by reverse splicing. CircRNA does not have a 5' end cap and a 3' end poly (A) tail. Through exon cyclization or intron cyclization, the 3' and 5' ends are connected to form a complete circular structure to avoid degradation by nuclease exonucleases. Therefore, it is more stable and more conservative than linear RNA. Circular RNA has a closed circular structure, a longer half-life than linear RNA, specific reverse splicing sites, tissue expression specificity, disease specificity, etc.; most of them exist in the cytoplasm, and a small part exists in the nucleus; and most of them are non-coding RNA, and the sequence is highly conserved; but the overall expression abundance is lower than mRNA; the proportion is still more than 10%. Combined with the above characteristics of circular RNA, the present invention uses the highly conservative characteristics of circular RNA sequences as a basis to accurately and correctly determine whether lung cancer is present; uses the characteristics of circular RNA circular structure that is not degraded by nuclease exonucleases as a basis to reduce the difficulty and cycle of experimental operation; but due to the disadvantage of low abundance of circular RNA, the LAMP technology with high amplification is used to compensate; due to the possibility of false positives in LAMP technology, the highly accurate CRISPR technology is used to supplement it, and the three complement each other. The present invention also optimizes and improves the LAMP+CRISPR two-stage reaction to a one-stage reaction, greatly reducing the result interpretation time. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 This is a comparison chart of the fluorescence values of lung cancer samples and non-lung cancer samples. DETAILED DESCRIPTION
[0041] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.
[0042] To further illustrate the technical means and effects of the present invention, the present invention is further described below in conjunction with the embodiments. Take the blood sample of lung cancer patient No. 1 (from social cancer volunteers), the blood sample of lung cancer patient No. 2 (from social cancer volunteers), the blood sample of non-lung cancer patients (from social cancer volunteers), and the healthy blood sample (from volunteers) as an example. The blood sample of lung cancer patient No. 1 and the blood sample of lung cancer patient No. 2 are used as positive tests, the blood sample of non-lung cancer patients is used as a specific test, and the healthy blood sample is used as a negative test.
[0043] Example 1 Peripheral blood sample preparation
[0044] When drawing blood samples, use a vacuum blood collection tube containing heparin liquid or heparin powder. Centrifuge at 5000rpm for 3min and take the supernatant to remove red blood cells, white blood cells, platelets, etc. from the blood. This is the sample to be tested. Take the blood sample of lung cancer patient No. 1, the blood sample of lung cancer patient No. 2, the blood sample of non-lung cancer patient, and the healthy blood sample as examples. Among them, the blood sample of lung cancer patient No. 1 and the blood sample of lung cancer patient No. 2 are used as positive tests, the blood sample of non-lung cancer patient is used as a specific test, and the healthy blood sample is used as a negative test. Centrifuge at 5000rpm for 3min and take the supernatant to obtain the blood sample of lung cancer patient No. 1 to be tested, the blood sample of lung cancer patient No. 2 to be tested, the blood sample of non-lung cancer patient to be tested, and the healthy blood sample to be tested.
[0045] Example 2 sgRNA design
[0046] The corresponding sgRNA (SEQ ID NO: 1) was designed according to the cricRNA marker SEQ ID NO: 9; all primers were synthesized by Wuhan Jinkairui Bioengineering Co., Ltd. The sgRNA sequence is shown in Table 1.
[0047]
[0048] The corresponding LAMP primers (SEQ ID NOs: 2-7) were designed according to the cricRNA marker SEQ ID NO: 9; all primers were synthesized by Wuhan Jinkairui Bioengineering Co., Ltd. The LAMP primer sequences are shown in Table 2.
[0049]
[0050] Example 3 Synthesis of fluorescent labeled probes
[0051] The probe was designed to be labeled with FAM at the 5' end and BHQ1 at the 3' end, and the sequence is shown in Table 3. All primers were synthesized by Wuhan Jinkairui Bioengineering Co., Ltd.
[0052]
[0053] Example 4 Sample Detection
[0054] 1. LAMP-CRISPR master mix preparation
[0055] LAMP-CRISPR premix: Tris-HCl PH8.0 20mM, (NH4)2SO4 5mM, KCl 10mM, betaine 400mM, MgSO4 8mM, Triton-X100 0.1%, BSA 100μg / mL, Bst DNA polymerase (Lexi Biotechnology, P001S) 1.6U / μL, reverse transcriptase (Lexi Biotechnology, P004S) 1U / μL, Cas12b (Lexi Biotechnology, C005S) 10nM.
[0056] 2. Configuration of the system to be tested
[0057] Take 1ul of each of the lung cancer patient blood sample No. 1 to be tested, the lung cancer patient blood sample No. 2 to be tested, the non-lung cancer patient blood sample to be tested, and the healthy blood sample to be tested in Example 1 and add them to the above 15ul LAMP-CRISPR premix, and add 120ng sgRNA, 1.4mM FIP primer, 1.4mM BIP primer, 0.2mM F3 primer, 0.2mM B3 primer, 0.4mM LF primer, 0.4mM LB primer, and 0.5μM fluorescent labeled probe; finally, add enzyme-free water to 20ul system. Add 15ul mineral oil to seal.
[0058] 3. Testing and interpretation of test results
[0059] The sample to be tested after the above configuration is placed in a fluorescence detector with a constant temperature function at 65°C for 30 minutes; the presence of lung cancer markers is determined based on the fluorescence value. The test results are shown in Table 4.
[0060]
[0061] The interpretation results are as follows: The fluorescence values of lung cancer patients No. 1 and No. 2 changed significantly, and were significantly higher than those of non-lung cancer patients and healthy blood, reaching the plateau period in about 15-20 minutes. The lung cancer marker content in the blood of lung cancer patients No. 1 and No. 2 was significantly higher than that of non-lung cancer patients and healthy blood, see Figure 1 .
[0062] Conclusion: (1) There is no significant difference in fluorescence value between lung cancer patient No. 1 and lung cancer patient No. 2; (2) There is a significant difference in fluorescence between lung cancer patient No. 1, lung cancer patient No. 2, non-lung cancer patients, and healthy blood; the above results prove that the lung cancer marker of the present invention has a high correlation with lung cancer, has the characteristics of high specificity and high accuracy, and the whole set of operations only takes 40-50 minutes to interpret the results, which is timely and convenient.
[0063] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
[0064]
[0065]
[0066]
[0067]
[0068]
Claims
1. A LAMP primer set, characterized in that: The LAMP primer set includes: FIP with a nucleotide sequence of SEQ ID NO: 2, BIP with a nucleotide sequence of SEQ ID NO: 3, F3 with a nucleotide sequence of SEQ ID NO: 4, and B3 with a nucleotide sequence of SEQ ID NO:
5.
2. A LAMP primer set according to claim 1, characterized in that: The LAMP primer set may optionally include the following loop primers: LF having a nucleotide sequence of SEQ ID NO:6 and LB having a nucleotide sequence of SEQ ID NO:
7.
3. A sgRNA, characterized in that The cricRNA marker is designed based on the nucleotide sequence of SEQ ID NO: 9 and specifically binds to the Cas12b protein.
4. The sgRNA according to claim 3, characterized in that The nucleotide sequence is SEQ ID No:
1.
5. A LAMP-CRISPR kit, characterized in that: Comprising the LAMP primer set according to claim 1 or 2, the sgRNA according to claim 3 or 4, the Cas12b protein, a reverse transcriptase, a DNA polymerase, a fluorescently labeled probe and a LAMP-CRISPR premix; The LAMP-CRISPR premix contains: Bst DNA polymerase at a concentration of 0.4U / μL to 1.6U / μL; reverse transcriptase at a concentration of 0.5U / μL to 1U / μL; Cas12b at a concentration of 1nM to 15nM; and a buffer; Preferably, the DNA polymerase is BST DNA polymerase or M-MLV, preferably Bst DNA polymerase at a concentration of 0.4U / μL to 1.6U / μL; Preferably, the LAMP-CRISPR premix comprises: DNA polymerase 1.6U / μL, reverse transcriptase 1U / μL, Cas12b 10nM and buffer; Preferably, the buffer comprises: Tris-HCl PH8.0 1mM~40mM, (NH4)2SO4 5mM~15mM; KCl 5mM~100mM, betaine 100mM~1.5M, MgSO4 2mM~25mM, Triton-X100 0.01%~1%, BSA concentration is 10μg / mL~500μg / mL; Preferred are: Tris-HCl pH 8.0 20 mM, (NH 4 ) 2 SO 4 5 mM, KCl 10 mM, betaine 400 mM, MgSO 4 8 mM, Triton-X 100 0.1% and BSA 100 μg / mL.
6. A LAMP-CRISPR kit according to claim 5, characterized in that: The nucleotide sequence of the fluorescent labeling probe is shown in SEQ ID NO: 8; preferably, the added amount is 0.1 μM to 1 μM, preferably 0.5 μM.
7. A LAMP-CRISPR kit according to claim 5, characterized in that: Said The concentration of each primer in the LAMP primer set is: The concentration of FIP primer is 0.8mM to 3.2mM; The concentration of BIP primer ranged from 0.8 mM to 3.2 mM; The concentration of F3 primer is 0.1mM to 0.4mM; The concentration of B3 primer is 0.1mM to 0.4mM; The concentration of LF primer is 0.2mM to 0.8mM; The concentration of LB primer is 0.2mM to 0.8mM; Preferably, the concentration of the FIP primer is 1.4 mM; The concentration of the BIP primer is 1.4 mM; and / or The concentration of the F3 primer is 0.2 mM; and / or The concentration of the B3 primer is 0.2 mM; and / or The concentration of LF primer is 0.4 mM; and / or The concentration of LB primer was 0.4 mM.
8. A LAMP-CRISPR kit as claimed in claim 5, characterized in that The reaction procedure is: react at 60-65°C for 15-30 minutes and then perform fluorescence detection.
9. Use of the LAMP primer set according to claim 1 or 2 and / or the sgRNA according to claim 3 or 4 in preparing a LAMP-CRISPR kit for detecting lung cancer markers in a sample.
10. The use according to claim 9, characterized in that The sample is peripheral blood, preferably a plasma sample obtained by adding an anticoagulant to peripheral blood after extraction and mixing, and taking the supernatant after centrifugation; preferably, the lung cancer marker is cricRNA with an amino acid sequence of SEQ ID NO:9.
Citation Information
Cited By
Method of detecting the presence of exon 8 of anril in a subject, kit, sets of oligonucleotides and their uses
EP4768603A1
Method of detecting the presence of exons 5 and 6 of anril in a subject, kit, sets of oligonucleotides and their uses
EP4768604A1
